Low-dose interleukin-2 as an add-on therapy to riluzole (Rilutek) led to a non-significant reduction in mortality in an ...

Compared to all-cause acute care and the general population, cannabis-related acute care is associated with a higher 5-year dementia risk.

The individuals who received acute care due to cannabis use retained an elevated risk of dementia compared to the total number of people who received care, excluding cases due to alcohol use.

Now, a large-scale study has linked heavy cannabis use with an increased risk of dementia. People aged over 45 who needed acute hospital care due to cannabis use had a 72% greater risk of ...

Hospital visits for cannabis use among people 45 and older were tied to higher dementia risk within 5 years. People who received acute care for cannabis use had a 23% higher dementia risk than all ...

Read about the findings of a Care Quality Commission report on the experiences of people with dementia using healthcare ...

5% and 19% of individuals aged 45 years or older with treatment for cannabis in acute care were diagnosed with dementia within five and 10 years, respectively, compared to 3.6% and 14.8% in ...

They compared the diagnosis of incident dementia between patients receiving acute care for cannabis use and three other groups: Matched patients receiving all-cause acute care, the matched general ...

Health data held at ICES were used to compare new diagnoses of dementia for individuals with patterns of cannabis use that required acute care, defined as a visit to the emergency department (ED ...